دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Origins of Covid-19 — Why It Matters (and Why It Doesn’t)
Lawrence O. Gostin, J.D., and Gigi K. Gronvall, Ph.D.
doi : 10.1056/NEJMp2305081
Vol. 388 No. 25
Equity and Obesity Treatment — Expanding Medicaid-Covered Interventions
Hannah Stoops, M.D., M.P.H., and Mohammad Dar, M.D.
doi : 10.1056/NEJMp2303268
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Amit Anand, M.D., Sanjay J. Mathew, M.D., Gerard Sanacora, M.D., Ph.D., James W. Murrough, M.D., Ph.D., Fernando S. Goes, M.D., Murat Altinay, M.D., Amy S. Aloysi, M.D., Ali A. Asghar-Ali, M.D., Brian S. Barnett, M.D., Lee C. Chang, M.D., Katherine A. Collins, M.S.W., Ph.D., Sara Costi, M.D., Sidra Iqbal, M.S., Manish K. Jha, M.D., Kamini Krishnan, Ph.D., Donald A. Malone, M.D., Sina Nikayin, M.D., Steven E. Nissen, M.D., Robert B. Ostroff, M.D., Irving M. Reti, M.D., Samuel T. Wilkinson, M.D., Kathy Wolski, M.P.H., and Bo Hu, Ph.D.
doi : 10.1056/NEJMoa2302399
Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain.
Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal
Leslie W. Young, M.D., Songthip T. Ounpraseuth, Ph.D., Stephanie L. Merhar, M.D., Zhuopei Hu, M.S., Alan E. Simon, M.D., Andrew A. Bremer, M.D., Ph.D., Jeannette Y. Lee, Ph.D., Abhik Das, Ph.D., Margaret M. Crawford, B.S., Rachel G. Greenberg, M.D., P. Brian Smith, M.D., Brenda B. Poindexter, M.D., Rosemary D. Higgins, M.D., Michele C. Walsh, M.D., Ward Rice, M.D., Ph.D., David A. Paul, M.D., Jessie R. Maxwell, M.D., Sucheta Telang, M.D., Camille M. Fung, M.D., Tanner Wright, M.D., Anne Marie Reynolds, M.D., Devon W. Hahn, M.D., Julie Ross, M.D., Jennifer M. McAllister, M.D., Moira Crowley, M.D., Sophie K. Shaikh, M.D., Karen M. Puopolo, M.D., Ph.D., Lori Christ, M.D., Jaime Brown, M.D., Julie Riccio, M.D., Kara Wong Ramsey, M.D., Akshatha, M.D., Erica F. Braswell, M.D., Lauren Tucker, M.D., Karen R. McAlmon, M.D., Krishna Dummula, M.D., Julie Weiner, M.D., Jessica R. White, M.D., Meghan P. Howell, M.D., Sarah Newman, A.P.R.N., D.N.P., Jessica N. Snowden, M.D., and Lori A. Devlin, D.O. for the ACT NOW Collaborative*
doi : 10.1056/NEJMoa2214470
Although clinicians have traditionally used the Finnegan Neonatal Abstinence Scoring Tool to assess the severity of neonatal opioid withdrawal, a newer function-based approach — the Eat, Sleep, Console care approach — is increasing in use. Whether the new approach can safely reduce the time until infants are medically ready for discharge when it is applied broadly across diverse sites is unknown.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Javier Bolaños-Meade, M.D., Mehdi Hamadani, M.D., Juan Wu, M.S., Monzr M. Al Malki, M.D., Michael J. Martens, Ph.D., Lyndsey Runaas, M.D., Hany Elmariah, M.D., Andrew R. Rezvani, M.D., Mahasweta Gooptu, M.D., Karilyn T. Larkin, M.D., Brian C. Shaffer, M.D., Najla El Jurdi, M.D., Alison W. Loren, M.D., Melhem Solh, M.D., Aric C. Hall, M.D., Amin M. Alousi, M.D., Omer H. Jamy, M.D., Miguel-Angel Perales, M.D., Janny M. Yao, Pharm.D., Kristy Applegate, M.B.A., Ami S. Bhatt, M.D., Leslie S. Kean, M.D., Yvonne A. Efebera, M.D., Ran Reshef, M.D., William Clark, M.D., Nancy L. DiFronzo, Ph.D., Eric Leifer, Ph.D., Mary M. Horowitz, M.D., Richard J. Jones, M.D., and Shernan G. Holtan, M.D. for the BMT CTN 1703 Investigators*
doi : 10.1056/NEJMoa2215943
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A phase 2 study indicated the potential superiority of a post-transplantation regimen of cyclophosphamide, tacrolimus, and mycophenolate mofetil.
Second-Line Switch to Dolutegravir for Treatment of HIV Infection
Loice A. Ombajo, M.B., Ch.B., M.Med., Jeremy Penner, M.D., Joseph Nkuranga, M.B., Ch.B., Jared Mecha, M.B., Ch.B., M.Med., Margaret Mburu, M.P.H., Collins Odhiambo, Ph.D., Florentius Ndinya, M.B., Ch.B., M.Med., Rukia Aksam, M.B., Ch.B., Richard Njenga, B.Sc., Simon Wahome, M.Pharm., Peter Muiruri, M.B., Ch.B., Sheila Eshiwani, M.B., Ch.B., Maureen Kimani, M.B., Ch.B., Catherine Ngugi, M.B., Ch.B., and Anton Pozniak, M.B., Ch.B., M.D.
doi : 10.1056/NEJMoa2210005
Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype information and who have viral suppression with second-line therapy containing a ritonavir-boosted PI have been limited.
A Dual-Chamber Leadless Pacemaker
Reinoud E. Knops, M.D., Ph.D., Vivek Y. Reddy, M.D., James E. Ip, M.D., Rahul Doshi, M.D., Derek V. Exner, M.D., M.P.H., Pascal Defaye, M.D., Robert Canby, M.D., Maria Grazia Bongiorni, M.D., Morio Shoda, M.D., Gerhard Hindricks, M.D., Petr Neužil, M.D., Mayer Rashtian, M.D., Karel T.N. Breeman, M.D., Jordan R. Nevo, M.S., Leonard Ganz, M.D., Chris Hubbard, M.B.A., and Daniel J. Cantillon, M.D. for the Aveir DR i2i Study Investigators*
doi : 10.1056/NEJMoa2300080
Single-chamber ventricular leadless pacemakers do not support atrial pacing or consistent atrioventricular synchrony. A dual-chamber leadless pacemaker system consisting of two devices implanted percutaneously, one in the right atrium and one in the right ventricle, would make leadless pacemaker therapy a treatment option for a wider range of indications.
Type I Cryoglobulinemic Vasculitis
Lucy Chapman, M.B., B.Ch., B.A.O., and Gerard M. Crotty, M.B.
doi : 10.1056/NEJMicm2213159
Case 19-2023: An 80-Year-Old Man with Left Foot Drop
Paloma González-Pérez, M.D., Ph.D., Karen A. Buch, M.D., and Reza Sadjadi, M.D.
doi : 10.1056/NEJMcpc2211512
Ketamine and ECT in Depression — Risks and Rewards
Robert Freedman, M.D.
doi : 10.1056/NEJMe2305130
Hush Little Baby — Promise of the Eat, Sleep, Console Approach
Wanda D. Barfield, M.D., M.P.H.
doi : 10.1056/NEJMe2304989
